On product labels, non-GMO status should pair nicely with Marine Stewardship Council certification.
As part of its mission towards 100% product traceability, krill oil supplier Aker BioMarine Antarctic US Inc. (Issaquah, WA) has applied for non-GMO status with the Non-GMO Project. The company’s application is pending approval, but a result could come as early as next month.
“We want people to really understand what this ingredient is from start to finish,” says Becky Wright, Aker’s communication manager. “Consumers and manufacturers really needs to start asking the questions about traceability, like where is my fish oil or krill oil coming from? What species of fish are in my oil?”
Even though GMO status is already a concern with fish products, Wright says few fish oil and krill oil dietary supplements are promoting non-GMO status. One exception is New Chapter’s Wholemega fish oil supplement. If Aker successfully obtains non-GMO status, manufacturers of Superba krill oil products will be that much closer to having verified non-GMO krill supplements.
“While non-GMO status is already a huge trend in food, at the moment the trend is really trickling down to dietary supplements in a big way,” says Wright. “In fact, for the Non-GMO project, I think it’s one of their fastest growing segments.” The Non-GMO Project even has a running list of non-GMO supplements and ingredients that bear its stamp of quality.
For Aker, non-GMO status would be just one of its several accomplishments in 2014. The company just announced plans to open a new manufacturing facility in Houston. Instead of performing oil extractions in Valencia, Spain, Aker will be able to send its Antarctic krill straight to the United States for local extraction before shipment. “Made in USA” claims may then become possible.
Robby Gardnerâ¨
Associate Editorâ¨
Nutritional Outlook magazine
â¨robby.gardner@ubm.com
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.